Pendekatan Terapi Asthma-COPD Overlap (ACO)

Muhammad Amin, Alamsyah Sitepu

= http://dx.doi.org/10.20473/jr.v3-I.3.2017.97-105
Abstract views = 128 times | views = 914 times

Abstract


Asthma and COPD are the most common chronic airways disease and have different clinical manifestations and treatments. Asthma is an airway inflammatory disease mediated by Th2 cytokines, CD4 + lymphocytes and eosinophils, whereas inflammation of COPD is affected by Th1 cytokines, CD8 + lymphocytes and neutrophils. Asthma-COPD overlap (ACO) is the presence of persistent airflow limitations with some symptoms resembling asthma and some other symptoms similar to COPD. Current treatment of ACO is to target the dominant inflammatory phenotype of eosinophils and neutrophils. Treatments given to patients with dominant eosinophil phenotype are inhaled and anti-IgE corticosteroids, and the drugs under reasearch are anti-IL-5, anti-IL-13, GATA3 inhibitors, anti-IL-33, anti-IL-25 and anti-thymic stromal lymphopoietin (anti-TSLP). Treatment given to patients with dominant neutrophil phenotype was macrolide, and treatment under reasearch was anti-IL-1, anti-IL-17A, anti-IL-23, CXCR2 antagonists, p38 MAPK inhibitor / JAK inhibitors and PDE4 inhibitors. Paucygranulocyte patient were given LAMA, LAMA + LABA therapy and bronchial thermoplasty. The therapy currently under study for this group is triple inhalation.


Keywords


Asthma, COPD, ACO, inflammatory phenotype

Full Text:

PDF

References


Bujarski S, Parulekar AD, Sharafkhaneh A, Hanania NA. The Asthma COPD Overlap Syndrome (ACOS) ; Current Allergy Asthma Rep,2015; 15: 7

Papaiwannou A, Zarogoulidis P, Porpodis K,et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) : current literature review. J Thorac Dis 2014 ; 6(S1) : S146-S151

Barrecheguren M, Esquinas C, Miravitless M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS); Curr Opin Pulm Med 2015, 21:74–79

Barnes P. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes : Mechanisms of allergic disease, National Heart and Lung Institute. 2015, p 531–545

Global Initiative for Asthma (GINA) guidelines. 2015. Available at : www.ginasthma.org Accessed March 10,2016

Perhimpunan Dokter Paru Indonesia. Asma, Pedoman Diagnosis dan Penatalaksanaan di Indonesia. PDPI.2003

Broaddus VC, Mason RJ, Ernst JD, et al. Murray and Nadel’s Textbook of Respiratory Medicine, Sixth Edition, 2016, p 731–750; 767–785.

Global Initiative for chronic obstructive lung disease (GOLD). 2015. Available at : www.goldcopd.org Accessed March 10, 2016

Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease. Asthma COPD and Asthma-COPD Overlap Syndrome (ACOS). 2015. Available from : http://www. ginasthma.org/asthma-copd-and-asthma-copd-overlap-syndromeacos/ Accessed May 10,2016

Barrecheguren M, Esquinas C, Miravitlles M. The Asthma-COPD overlap syndrome : a new entity? COPD Research and Practise 2015 ; 1:8

Zeki AA, Schivo M, Chan A, Albertson TE, Louie S. The Asthma-COPD Overlap Syndrome : A Common Clinical Problem in the Elderly. Journal of Allergy, Hindawi Publishing Corporation, 2011

Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI and Senior RM. Fishman’s Pulmonary Diseases and Disorders, Fifth Edition, 2015. p 700-714

Wurst KE, Kelly-Reif K, Bushnell GA, Pascoe S, Barnes N. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome ; Respiratory Medicine 2016, 110 : 1–11

Postma DS, Weiss ST, van den Berge M, Kerstjens HAM, Koppelman GH. Revisiting the Dutch hypothesis; J Allergy Clin Immunol 2015; 136: 521–9

Anthonisen NR. The British hypothesis revisited. Eur Respir J 2004; 23:657–658

Vestbo J, Hogg JC. Convergence of the Epidemiology and Pathology of COPD; Thorax 2006; 61:86–88

Suzuki T, Tada Y, Kawata N, Matsuura Y et al. Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome; International Journal of COPD 2015; 10: 947–954

Postma DS, Boezen HM. Rationale for the Dutch Hypothesis, Allergy and Airway Hyperresponsiveness as Genetic Factors and Their Interaction With Environment in the Development of Asthma and COPD; Chest 2004; 126 : 96S–104S

Durham A, Caramori G, Chung K, Adcock I. Targeted antiinflammatory therapeutics in asthma and chronic obstructive lung disease. Translational Research 2016;167: 192–203

Garcia G, Taille C, Laveneziana P, Bourdin A, Chanez P dan Humbert M. Anti Interleukin-5 therapy in severe asthma. Eur Respir Rev 2013; 22:251–257

Corren J. Anti Interleukin-13 antibody therapy for asthma : one step closer. Eur Respir J ; 41: 255–56

Gauvreau GM, O’Byrne PM, Boule LP, Wang Y, Cockroft D et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses; N Engl J Med 2014; 370:2102–10

Page CP. Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease; Int Arch Allergy Immunol 2014; 165: 152–164

Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet,2005; 365: 167–75

Sevilla-Sanchez D, Soy-Muner D, Soler-Porcar N. Usefulness of Macrolides as Anti-inflammatories in Respiratory Diseases; Arch Bronconeumol 2010; 46(5) : 244–254

Barnes PJ. Role of HDAC2 in the Pathophysiology of COPD. Annu. Rev.Physiol; 2009; 71:451–64

Trivedi A, Pavord I, Castro M. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma : review. Lancet Respir Med 2016 ; Published Online May 23,2016


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Jurnal Respirasi

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Satats

Indexed by: